Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Fda Inspections
  6. /
  7. K.C. Pharmaceuticals, Inc
FDA Inspection
•K.C. Pharmaceuticals, Inc•February 13, 2023

K.C. Pharmaceuticals, Inc – FDA Inspection, Feb 13, 2023

Record Details

This FDA Inspection record concerns K.C. Pharmaceuticals, Inc, with an inspection on February 13, 2023, issued by the Center for Drug Evaluation and Research, covering drugs.

Company
K.C. Pharmaceuticals, Inc
Inspection Date
February 13, 2023
Product Type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Amir Alavi (Company Rep)
  • Christopher R. Czajka (FDA Associated Person)
  • Lawrence R. Deyton (FDA Associated Person)
View Company Profile

ID · f2890018-3936-4ea6-93ba-08683d11590a

Inspection Facts

Official Action Indicated (OAI)

Significant objectionable conditions were found and regulatory or administrative action is recommended.

Inspection number
1197242
FDA center
Human Drugs
Project area
Drug Quality Assurance
Outcome
Form 483 issued, view the record

FDA Citations

20
  1. 21 CFR 211.42(c)(10)(v)Cleaning System
  2. 21 CFR 211.110(a)Control procedures to monitor and validate performance
  3. 21 CFR 211.67(a)Cleaning / Sanitizing / Maintenance
  4. 21 CFR 211.46(b)Equipment for Environmental Control
  5. 21 CFR 211.160(b)Scientifically sound laboratory controls
  6. 21 CFR 211.194(a)(8)Second person sign off
  7. 21 CFR 211.198(a)Complaint Handling Procedure
  8. 21 CFR 211.113(b)Validation lacking for sterile drug products
  9. 21 CFR 211.22(d)Procedures not in writing, fully followed
  10. 21 CFR 211.165(e)Test methods

Showing 10 of 20 citations.

Full citation text and observation details available on the Dashboard.

Other FDA inspections of K.C. Pharmaceuticals, Inc

10
DateClassificationOfficeProject area
February 13, 2026Not classifiedLos Angeles District OfficeDrug Quality Assurance
August 28, 2024VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
January 30, 2020VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
November 16, 2017VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
March 19, 2015VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
View all 10 other inspections on the company page
Other documents for K.C. Pharmaceuticals, Inc
  • FDA Inspection 1294070 - 2026-02-13
  • FDA Inspection 1247201 - 2024-08-28
  • FDA Inspection 1116341 - 2020-01-30
  • FDA Inspection 1032267 - 2017-11-16
  • FDA Inspection 923526 - 2015-03-19

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore K.C. Pharmaceuticals, Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.